Press Releases

Sep 03, 2021	Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
Sep 02, 2021	Ionis to present at upcoming virtual investor conferences
Aug 04, 2021	Ionis reports second quarter 2021 financial results and recent business achievements
Aug 02, 2021	Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Jul 29, 2021	Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
Jul 26, 2021	Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
Jul 21, 2021	Ionis to hold second quarter 2021 financial results webcast
Jul 13, 2021	Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
Jun 14, 2021	Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
Jun 10, 2021	Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
Jun 02, 2021	Ionis announces changes to its board of directors at annual meeting of stockholders
May 26, 2021	Ionis to present at upcoming investor conferences
May 06, 2021	Ionis to present at upcoming investor conferences
May 05, 2021	Ionis to host 2021 virtual annual meeting of stockholders
May 05, 2021	Ionis reports first quarter 2021 financial results and recent business achievements
Apr 21, 2021	Ionis to hold first quarter 2021 financial results webcast
Apr 20, 2021	Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
Apr 08, 2021	Ionis prices private placement of convertible senior notes
Apr 06, 2021	Ionis announces proposed private placement of convertible notes
Apr 05, 2021	Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Mar 29, 2021	Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
Mar 26, 2021	Ionis to present at upcoming investor conferences
Mar 22, 2021	Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)
Mar 01, 2021	Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
Feb 24, 2021	Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
Feb 19, 2021	Ionis to present at upcoming investor conferences
Feb 11, 2021	Ionis to hold 2020 financial results webcast
Jan 07, 2021	Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Jan 05, 2021	Ionis to present at 39th Annual J.P. Morgan Healthcare Conference

Investor contact

Media contact

Press Releases

Press Releases

Investor contact

Media contact

Press Releases

Press Releases

Keyword Search